Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.38
ALQA's Cash to Debt is ranked lower than
59% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. ALQA: 1.38 )
Ranked among companies with meaningful Cash to Debt only.
ALQA' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 10000.00 Max: No Debt
Current: 1.38
Equity to Asset 0.61
ALQA's Equity to Asset is ranked lower than
53% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ALQA: 0.61 )
Ranked among companies with meaningful Equity to Asset only.
ALQA' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.84 Max: 0.99
Current: 0.61
0.57
0.99
F-Score: 4
Z-Score: -1.80
M-Score: -1.57
WACC vs ROIC
18.60%
-83.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -161.83
ALQA's Operating margin (%) is ranked lower than
90% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. ALQA: -161.83 )
Ranked among companies with meaningful Operating margin (%) only.
ALQA' s Operating margin (%) Range Over the Past 10 Years
Min: -1119.69  Med: -464.77 Max: -188.19
Current: -161.83
-1119.69
-188.19
Net-margin (%) -148.20
ALQA's Net-margin (%) is ranked lower than
90% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. ALQA: -148.20 )
Ranked among companies with meaningful Net-margin (%) only.
ALQA' s Net-margin (%) Range Over the Past 10 Years
Min: -1222.3  Med: -465.38 Max: -172.97
Current: -148.2
-1222.3
-172.97
ROE (%) -55.87
ALQA's ROE (%) is ranked lower than
89% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. ALQA: -55.87 )
Ranked among companies with meaningful ROE (%) only.
ALQA' s ROE (%) Range Over the Past 10 Years
Min: -312.57  Med: -70.75 Max: -19.76
Current: -55.87
-312.57
-19.76
ROA (%) -33.35
ALQA's ROA (%) is ranked lower than
87% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. ALQA: -33.35 )
Ranked among companies with meaningful ROA (%) only.
ALQA' s ROA (%) Range Over the Past 10 Years
Min: -2368.45  Med: -89.26 Max: -19.42
Current: -33.35
-2368.45
-19.42
ROC (Joel Greenblatt) (%) -1408.35
ALQA's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.79 vs. ALQA: -1408.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALQA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -53854.55  Med: -1397.71 Max: -114.61
Current: -1408.35
-53854.55
-114.61
Revenue Growth (3Y)(%) 41.90
ALQA's Revenue Growth (3Y)(%) is ranked higher than
93% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ALQA: 41.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALQA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 41.9
Current: 41.9
0
41.9
EBITDA Growth (3Y)(%) 8.60
ALQA's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. ALQA: 8.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALQA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.1  Med: 15.75 Max: 105.6
Current: 8.6
-38.1
105.6
EPS Growth (3Y)(%) 7.40
ALQA's EPS Growth (3Y)(%) is ranked higher than
51% of the 509 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ALQA: 7.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALQA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.8  Med: 24.20 Max: 113.3
Current: 7.4
-30.8
113.3
» ALQA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

ALQA Guru Trades in

Q3 2015

ALQA Guru Trades in Q3 2015

Jim Simons 15,900 sh (New)
» More
Q4 2015

ALQA Guru Trades in Q4 2015

Jim Simons 20,000 sh (+25.79%)
» More
Q1 2016

ALQA Guru Trades in Q1 2016

Jim Simons 137,800 sh (+589.00%)
» More
» Details

Insider Trades

Latest Guru Trades with ALQA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NAS:NVGN, OTCPK:NNAB, NAS:TNXP, OTCPK:SUWN, NAS:PRPH, NAS:ECTE, AMEX:AXN, OTCPK:NEVPF, OTCPK:INNV, NAS:IMNP, NAS:NTEC, OTCPK:CHEXF, OTCPK:PMXSF, AMEX:CPHI, NAS:BSPM, OTCPK:ATHJF, OTCPK:INBP, NAS:ALIM, OTCPK:NUIN, OTCPK:ADIA » details
Alliqua BioMedical Inc is a biomedical company providing wound care solutions. It is also engaged in contract manufacturing.

Alliqua BioMedical Inc a Florida corporation formed on October 21, 1997. It is a biomedical company through its subsidiary providing advanced wound care solutions. The Company's core business includes; advanced wound care and contract manufacturing. The Company develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its subsidiary manufactures and markets its hydrogel products. Its products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable it to produce gels that can satisfy rigid tolerance specifications with respect to a range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. In July 2012, it began to market two proprietary products, SilverSeal, a hydrogel wound dressing with silver coated fibers, and Hydress, an over-the-counter hydrogel wound dressing. It supplies these gels mainly to the wound care segment of the healthcare industry. The Company's SilverSeal and Hydress dressings are each currently available in two sizes and are used to provide and maintain a moist wound environment. SilverSeal dressings also provide an antimicrobial barrier. On November 14, 2013 Company entered into a license, marketing and development agreement with Anthrogenesis Corporation, Celgene Cellular Therapeutics ("CCT"), an affiliate of Celgene Corporation, pursuant to which CCT granted an exclusive, royalty-bearing license in its intellectual property related to certain placental based products, including the wound care products Extracellular Matrix ("ECM"), a suite of advanced wound management products made from extracellular matrix derived from the human placenta and Biovance, a collagen-based decellularized and dehydrated topical wound covering produced from human amniotic membrane for the management of non-infected partial- and full-thickness wounds; and also into a supply agreement with CCT, pursuant to which CCT will supply Company with the entire requirement of Biovance for distribution and sale in the United States. The Company's medical devices are subject to the U.S. Food and Drug Administration's general controls, which include compliance with the applicable portions of the U.S. Food and Drug Administration's Quality System Regulation, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the U

Ratios

vs
industry
vs
history
P/B 0.68
ALQA's P/B is ranked higher than
92% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. ALQA: 0.68 )
Ranked among companies with meaningful P/B only.
ALQA' s P/B Range Over the Past 10 Years
Min: 0.42  Med: 1.73 Max: 23.18
Current: 0.68
0.42
23.18
P/S 1.56
ALQA's P/S is ranked higher than
66% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. ALQA: 1.56 )
Ranked among companies with meaningful P/S only.
ALQA' s P/S Range Over the Past 10 Years
Min: 1.01  Med: 10.85 Max: 38.71
Current: 1.56
1.01
38.71
Current Ratio 2.29
ALQA's Current Ratio is ranked lower than
54% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. ALQA: 2.29 )
Ranked among companies with meaningful Current Ratio only.
ALQA' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.29 Max: 96.93
Current: 2.29
0.04
96.93
Quick Ratio 1.96
ALQA's Quick Ratio is ranked higher than
53% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. ALQA: 1.96 )
Ranked among companies with meaningful Quick Ratio only.
ALQA' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 1.96 Max: 96.93
Current: 1.96
0.04
96.93
Days Inventory 161.07
ALQA's Days Inventory is ranked lower than
72% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. ALQA: 161.07 )
Ranked among companies with meaningful Days Inventory only.
ALQA' s Days Inventory Range Over the Past 10 Years
Min: 23.63  Med: 62.95 Max: 137.1
Current: 161.07
23.63
137.1
Days Sales Outstanding 52.06
ALQA's Days Sales Outstanding is ranked higher than
70% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. ALQA: 52.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALQA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.55  Med: 33.21 Max: 73.9
Current: 52.06
13.55
73.9
Days Payable 129.73
ALQA's Days Payable is ranked higher than
79% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.79 vs. ALQA: 129.73 )
Ranked among companies with meaningful Days Payable only.
ALQA' s Days Payable Range Over the Past 10 Years
Min: 47.93  Med: 121.94 Max: 196.17
Current: 129.73
47.93
196.17

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.15
ALQA's Price/Median PS Value is ranked higher than
98% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. ALQA: 0.15 )
Ranked among companies with meaningful Price/Median PS Value only.
ALQA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.98 Max: 3.03
Current: 0.15
0.11
3.03
Earnings Yield (Greenblatt) (%) -91.80
ALQA's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ALQA: -91.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALQA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -421.86  Med: 0.00 Max: 0
Current: -91.8
-421.86
0

More Statistics

Revenue (TTM) (Mil) $17.57
EPS (TTM) $ -1.02
Beta2.09
Short Percentage of Float1.29%
52-Week Range $0.70 - 5.66
Shares Outstanding (Mil)28.98

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 23 29 39
EPS ($) -0.92 -0.76 -0.58
EPS w/o NRI ($) -0.92 -0.76 -0.58
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ALQA

Headlines

Articles On GuruFocus.com
CFO of Alliqua BioMedical Inc Buys 2,500 Shares Aug 12 2015 
Market Overlooks Alliqua’s First MAC Coverage Apr 21 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
ETF’s with exposure to Alliqua BioMedical, Inc. : June 21, 2016 Jun 21 2016
ETF’s with exposure to Alliqua BioMedical, Inc. : June 7, 2016 Jun 07 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Other Events Jun 06 2016
ALLIQUA BIOMEDICAL, INC. Financials May 26 2016
ETF’s with exposure to Alliqua BioMedical, Inc. : May 19, 2016 May 19 2016
Alliqua BioMedical, Inc. :ALQA-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
6 Stocks Under $10 Making Big Moves Higher May 18 2016
Alliqua BioMedical, Inc. to Attend Craig-Hallum Institutional Investor Conference May 16 2016
Alliqua BioMedical, Inc. to Attend Craig-Hallum Institutional Investor Conference May 16 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 10 2016
Alliqua reports 1Q loss May 10 2016
Alliqua reports 1Q loss May 10 2016
Alliqua BioMedical, Inc. Reports First Quarter Financial Results May 10 2016
Q1 2016 Alliqua BioMedical Inc Earnings Release - Before Market Open May 10 2016
Alliqua BioMedical, Inc. Reports First Quarter Financial Results May 10 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders,... May 06 2016
5 Breakout Stocks Under $10 Set to Soar May 05 2016
Integra (IART) Beats on Q1 Earnings, Grows Organically Apr 28 2016
Celgene Corporation (NASDAQ: CELG) CMO Joins MetaStat Inc (OTCQB: MTST) Board Apr 27 2016
Alliqua BioMedical, Inc. to Announce First Quarter of Fiscal Year 2016 Results on May 10th Apr 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)